The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
The MPTP Story
Open accessAbstract
The identification of MPTP, a relatively simple compound which causes selective degeneration of the substantia nigra after systemic administration, has had an a significant impact on the understanding and treatment of Parkinson’s disease (PD) over the last 30 years. This article is prefaced by the intriguing “medical detective story” that lead to the discovery of the biological effects of MPTP in humans. The steps that lead to the unraveling its mechanism of action and their impact on research into pathways underlying nigrostriatal degeneration are reviewed. The impact of the animal models that have been developed utilizing MPTP is also described with a focus on the translational implications of MPTP-related research. These include use of MAO-B inhibitors aimed at neuroprotection in PD and the importance of a stable primate model for PD which was utilized to better understand the circuitry of the basal ganglia, and the identification of the subthalamic nucleus as a target for deep brain stimulation. Finally, the results of a broad range of epidemiologic studies aimed as assessing the impact of environmental factors in PD that have been inspired by MPTP are summarized, including the discovery of other neurotoxicants (rotenone and paraquat) with parkinsonogenic effects. Overall, this article attempts to describe how the discovery of this nigral neurotoxicant began, where it is currently, and what the future may hold.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Self-citationPrimate models of movement disorders of basal ganglia origin
DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683
Frequency Dependence of Signal Power and Spatial Reach of the Local Field Potential
Leski, S., Lindén, H., Tetzlaff, T., Pettersen, K. H., & Einevoll, G. T. (2013) · PubMed · doi:10.18154/rwth-conv-084442 · Cited by 3,639
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Reversal of Experimental Parkinsonism by Lesions of the Subthalamic Nucleus
Bergman, H., Wichmann, T., & DeLong, M. R. (1990) · Science · doi:10.1126/science.2402638 · Cited by 1,907
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., & Marsden, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,756
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism
Bergman, H., Wichmann, T., Karmon, B., & DeLong, M. R. (1994) · Journal of Neurophysiology · doi:10.1152/jn.1994.72.2.507 · Cited by 1,365
Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein
Lotharius, J., & Brundin, P. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn983 · Cited by 1,283
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
Chiba, K., Trevor, A., & Castagnoli, N. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91293-2 · Cited by 1,097
Heikkila, R. E., Manzino, L., Cabbat, F. S., & Duvoisin, R. C. (1984) · Nature · doi:10.1038/311467a0 · Cited by 1,010
William Langston, J., Forno, L. S., Rebert, C. S., & Irwin, I. (1984) · Brain Research · doi:10.1016/0006-8993(84)90777-7 · Cited by 922
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
Markey, S. P., Johannessen, J. N., Chiueh, C. C., Burns, R. S., & Herkenham, M. A. (1984) · Nature · doi:10.1038/311464a0 · Cited by 786
Schapira, A. H. V., Mann, V. M., Cooper, J. M., Dexter, D., Daniel, S. E., Jenner, P., Clark, J. B., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb05809.x · Cited by 673
The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Tetrud, J. W., & Langston, J. W. (1989) · Science · doi:10.1126/science.2502843 · Cited by 638
Self-citationBallard, P. A., Tetrud, J. W., & Langston, J. W. (1985) · Neurology · doi:10.1212/wnl.35.7.949 · Cited by 629
Self-citationSnow, B. J., Rolfe, F. L., Lockhart, M. M., Frampton, C. M., O'Sullivan, J. D., Fung, V., Smith, R. A. J., Murphy, M. P., Taylor, K. M., & On behalf of the Protect Study Group (2010) · Movement Disorders · doi:10.1002/mds.23148 · Cited by 606
Pargyline Prevents MPTP-Induced Parkinsonism in Primates
Langston, J. W., Irwin, I., Langston, E. B., & Forno, L. S. (1984) · Science · doi:10.1126/science.6332378 · Cited by 581
Self-citationChen, P.-C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W., & Johnson, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813361106 · Cited by 579
Acute and Long-Term Effects of Subthalamic Nucleus Stimulation in Parkinson's Disease
Benabid, A. L., Pollak, P., Gross, C., Hoffmann, D., Benazzouz, A., Gao, D. M., Laurent, A., Gentil, M., & Perret, J. (1994) · Stereotactic and Functional Neurosurgery · doi:10.1159/000098600 · Cited by 532
Environmental Toxins and Parkinson's Disease
Goldman, S. M. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135937 · Cited by 505
Przedborski, S., Kostic, V, Jackson-Lewis, V, Naini, A., Simonetti, S., Fahn, S., Carlson, E., Epstein, C., & Cadet, J. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-05-01658.1992 · Cited by 456
Haas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W. (1995) · Annals of Neurology · doi:10.1002/ana.410370604 · Cited by 435
Langston, J. W., Irwin, I., Langston, E. B., & Forno, L. S. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90293-3 · Cited by 435
Self-citationTakahashi, N., Miner, L. L., Sora, I., Ujike, H., Revay, R. S., Kostic, V., Jackson-Lewis, V., Przedborski, S., & Uhl, G. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9938 · Cited by 429
The Parkinson Study Group QE3 Investigators, Beal, M. F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W. R., Haas, R., Juncos, J. L., Nutt, J. G., Voss, T. S., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.131 · Cited by 408
Cohen, G., Pasik, P., Cohen, B., Leist, A., Mytilineou, C., & Yahr, M. D. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90700-3 · Cited by 323
Ramsay, R. R., Salach, J. I., & Singer, T. P. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(86)80483-1 · Cited by 272
Sanders, L. H., Laganière, J., Cooper, O., Mak, S. K., Vu, B. J., Huang, Y. A., Paschon, D. E., Vangipuram, M., Sundararajan, R., Urnov, F. D., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.10.013 · Cited by 270
Self-citationMPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects.
Langston, J. W., Langston, E. B., & Irwin, I. (1984) · PubMed · Cited by 249
Self-citationRapid ATP Loss Caused by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mouse Brain
Chan, P., DeLanney, L. E., Irwin, I., Langston, J. W., & Di Monte, D. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02134.x · Cited by 241
Self-citationOffen, D., Beart, P. M., Cheung, N. S., Pascoe, C. J., Hochman, A., Gorodin, S., Melamed, E., Bernard, R., & Bernard, O. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5789 · Cited by 232
Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease
Bindoff, L. A., Birch-Machin, M. A., Cartlidge, N. E. F., Parker, W. D., & Turnbull, D. M. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90311-t · Cited by 229
Gehrke, S., Wu, Z., Klinkenberg, M., Sun, Y., Auburger, G., Guo, S., & Lu, B. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2014.12.007 · Cited by 219
Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+
Ransom, B. R., Kunis, D. M., Irwin, I., & Langston, J. W. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90543-x · Cited by 209
Self-citationRamsay, R. R., Krueger, M. J., Youngster, S. K., Gluck, M. R., Casida, J. E., & Singer, T. P. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb11409.x · Cited by 209
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
Schapira, A. H., McDermott, M. P., Barone, P., Comella, C. L., Albrecht, S., Hsu, H. H., Massey, D. H., Mizuno, Y., Poewe, W., Rascol, O., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70117-0 · Cited by 203
Milestones in research on the pathophysiology of Parkinson's disease
Wichmann, T., DeLong, M. R., Guridi, J., & Obeso, J. A. (2011) · Movement Disorders · doi:10.1002/mds.23695 · Cited by 197
The MPTP-lesioned non-human primate models of Parkinson’s disease. Past, present, and future
Fox, S. H., & Brotchie, J. M. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84007-5 · Cited by 191
Caenorhabditis elegans MPP+ Model of Parkinson’s Disease for High-Throughput Drug Screenings
Braungart, E., Gerlach, M., Riederer, P., Baumeister, R., & Hoener, M. C. (2004) · Neurodegenerative Diseases · doi:10.1159/000080983 · Cited by 186
Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons
McKinley, E. T., Baranowski, T. C., Blavo, D. O., Cato, C., Doan, T. N., & Rubinstein, A. L. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2005.08.014 · Cited by 182
Ramsay, R. R., Dadgar, J., Trevor, A., & Singer, T. P. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90037-8 · Cited by 181
Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys
Lavoie, B., & Parent, A. (1991) · NeuroReport · doi:10.1097/00001756-199110000-00012 · Cited by 162
Castagnoli, N., Chiba, K., & Trevor, A. J. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90063-3 · Cited by 153
Cognitive change following MPTP exposure
Stern, Y., Tetrud, J. W., Martin, W. R. W., Kutner, S. J., & Langston, J. W. (1990) · Neurology · doi:10.1212/wnl.40.2.261 · Cited by 146
Self-citationα-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates
Purisai, M. G., McCormack, A. L., Langston, J. W., Johnston, L. C., & Monte, D. A. D. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.05.028 · Cited by 142
Self-citationThe Neurotoxicity of 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in the Monkey and Man
Burns, R. S., Markey, S. P., Phillips, J. M., & Chiueh, C. C. (1984) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046345 · Cited by 142
Dopamine Neurons from Transgenic Mice with a Knockout of the p53 Gene Resist MPTP Neurotoxicity
Trimmer, P. A., Smith, T. S., Jung, A. B., & Bennett, J. P. (1996) · Neurodegeneration · doi:10.1006/neur.1996.0031 · Cited by 136
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys
Quik, M., Cox, H., Parameswaran, N., O'Leary, K., Langston, J. W., & Di Monte, D. (2007) · Annals of Neurology · doi:10.1002/ana.21203 · Cited by 133
Self-citationBlanchard, V., Raisman‐Vozari, R., Vyas, S., Michel, P. P., Javoy-Agid, F., Uhl, G. R., & Agid, Y. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90029-9 · Cited by 129
VMAT2 and dopamine neuron loss in a primate model of Parkinson’s disease
Chen, M., Kuwabara, H., Zhou, Y., Adams, R. J., Brašić, J. R., McGlothan, J. L., Verina, T., Burton, N. C., Alexander, M., Kumar, A., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05108.x · Cited by 124
Ramsay, R. R., Kowal, A. T., Johnson, M. K., Salach, J. I., & Singer, T. P. (1987) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(87)90531-5 · Cited by 115
Mitochondrial DNA analysis in Parkinson's disease
Schapira, A. H. V., Holt, I. J., Sweeney, M. G., Harding, A. E., Jenner, P. G., & MARSDEN, C. D. (1990) · Movement Disorders · doi:10.1002/mds.870050406 · Cited by 113
Ebadi, M., Brown‐Borg, H. M., Refaey, H. E., Singh, B. B., Garrett, S. H., Shaik, S., & Sharma, S. K. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.09.011 · Cited by 108
Advances in environmental epidemiology
Tanner, C. M. (2010) · Movement Disorders · doi:10.1002/mds.22721 · Cited by 95
Genetic modification of the association of paraquat and Parkinson's disease
Goldman, S. M., Kamel, F., Ross, G. W., Bhudhikanok, G. S., Hoppin, J. A., Korell, M., Marras, C., Meng, C., Umbach, D. M., Kasten, M., et al. (2012) · Movement Disorders · doi:10.1002/mds.25216 · Cited by 94
Self-citationBian, M., Liu, J., Hong, X., Yu, M., Huang, Y., Sheng, Z., Fei, J., & Huang, F. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039953 · Cited by 85
Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine on neostriatal dopamine in mice
Heikkila, R. E. (1984) · Neuropharmacology · doi:10.1016/0028-3908(84)90170-9 · Cited by 81
The Identification of Alpha-Synuclein as the First Parkinson Disease Gene
Nussbaum, R. L. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-179003 · Cited by 77
Mitochondrial DNA and Parkinson's disease
Monte, D. A. D. (1991) · Neurology · doi:10.1212/wnl.41.5_suppl_2.38 · Cited by 76
Jacobowitz, D. M., Rs, B., Chiueh, C. C., & Kopin, I. J. (1984) · PubMed · Cited by 73
Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain.
Riachi, N. J., LaManna, J. C., & Harik, S. I. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23492-9 · Cited by 70
Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline
Jenner, P. G., & Langston, J. W. (2011) · Movement Disorders · doi:10.1002/mds.23926 · Cited by 67
Self-citationModel fusion: The next phase in developing animal models for parkinson’s disease
Manning-Bog, A., & Langston, J. W. (2007) · Neurotoxicity Research · doi:10.1007/bf03033569 · Cited by 62
Self-citationSpeciale, S. G., Liang, C., Sonsalla, P. K., Edwards, R. H., & German, D. C. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00570-8 · Cited by 59
Targeting Mitochondria for Neuroprotection in Parkinson's Disease
Schapira, A. H. V. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4419 · Cited by 48
Wang, Y.-M., Pu, P., & Le, W.-D. (2007) · Neuroscience Bulletin · doi:10.1007/s12264-007-0049-3 · Cited by 43
Sandler, M. B., Glover, V. A. S., ASHFORD, A., et al. (1980) · Journal of Neural Transmission · doi:10.1007/bf01250659 · Cited by 34
Hauser, R. A., Li, R., Pérez, A., Ren, X., Weintraub, D., Elm, J. J., Goudreau, J. L., Morgan, J. C., Fang, J. Y., Aminoff, M. J., et al. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-160965 · Cited by 32
Cited by
Parkinson’s disease: etiopathogenesis and treatment
Jankovic, J., & Tan, E. K. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322338 · Cited by 1,169
The pathogenesis of Parkinson's disease
Morris, H. R., Spillantini, M. G., Sue, C. M., & Williams-Gray, C. H. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01478-2 · Cited by 1,019
Parkinson's Disease and the Environment
Ball, N., Teo, W.-P., Chandra, S., & Chapman, J. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00218 · Cited by 480
Oxidative stress and regulated cell death in Parkinson’s disease
Dionísio, P. A., Amaral, J. D., & Rodrigues, C. M. P. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101263 · Cited by 424
New insights into the complex role of mitochondria in Parkinson’s disease
Grünewald, A., Kumar, K. R., & Sue, C. M. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.09.003 · Cited by 364
Metadata
- Authors
- Langston, J. W.
- Venue
- Journal of Parkinson’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-03-06
- Volume
- 7
- Issue
- s1
- Pages
- S11-S19
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- OpenAlex
- W2593660881
- Cited by
- 424
- References
- 73
- FWCI
- 23.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.